Effects of canagliflozin on human myocardial redox signalling: clinical implications

Volume: 42, Issue: 48, Pages: 4947 - 4960
Published: Jul 19, 2021
Abstract
Aims Recent clinical trials indicate that sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in heart failure patients, but the underlying mechanisms remain unknown. We explored the direct effects of canagliflozin, an SGLT2 inhibitor with mild SGLT1 inhibitory effects, on myocardial redox signalling in humans. Methods and results Study 1 included 364 patients undergoing cardiac surgery. Right atrial appendage...
Paper Details
Title
Effects of canagliflozin on human myocardial redox signalling: clinical implications
Published Date
Jul 19, 2021
Volume
42
Issue
48
Pages
4947 - 4960
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.